Anemoside B4

1. Anemoside B4 activates PI3K–AKT signalling in mice.

   “AB4 directly interacted with SRC in both in vivo and in vitro settings, activating the PI3K/AKT/mTOR pathway”

   Animalsin SCM models

   Anemoside B4 ameliorates septic cardiomyopathy by activating SRC-mediated PI3K/AKT/mTOR pathway to alleviate mitochondrial dysfunction and cardiomyocyte senescence

   International immunopharmacology·5 Jan 2026

More on PI3K–AKT signalling

1. Anemoside B4 inhibits cellular senescence in mice.

   “AB4 also suppressed cardiomyocyte senescence, as indicated by diminished senescence markers and factors associated with the senescence-associated secretory phenotype (SASP).”

   Animalsin septic cardiomyopathy and LPS-stimulated cardiomyocytes

   Anemoside B4 ameliorates septic cardiomyopathy by activating SRC-mediated PI3K/AKT/mTOR pathway to alleviate mitochondrial dysfunction and cardiomyocyte senescence

   International immunopharmacology·5 Jan 2026

More on Cellular senescence

1. Anemoside B4 decreases inflammation in mice.

   “High-dose AB4 (AB4-H) demonstrated the most pronounced enhancements, reinstating myocardial integrity and diminishing inflammation, as indicated by echocardiogram and HE staining.”

   Animalsin LPS- and CLP-induced SCM

   Anemoside B4 ameliorates septic cardiomyopathy by activating SRC-mediated PI3K/AKT/mTOR pathway to alleviate mitochondrial dysfunction and cardiomyocyte senescence

   International immunopharmacology·5 Jan 2026

More on Inflammation

1. Anemoside B4 improves cardiac function in mice.

   “AB4 exhibited dose-dependent protection in both LPS- and CLP-induced SCM models, enhancing cardiac function and mitigating myocardial damage.”

   Animalsin LPS- and CLP-induced SCM

   Anemoside B4 ameliorates septic cardiomyopathy by activating SRC-mediated PI3K/AKT/mTOR pathway to alleviate mitochondrial dysfunction and cardiomyocyte senescence

   International immunopharmacology·5 Jan 2026